HIK Hikma Pharmaceuticals Plc

 

TIDMHIK 
 
RNS Number : 5829L 
Hikma Pharmaceuticals Plc 
14 January 2009 
 

 
 
Pre-close Trading Statement 
 
 
LONDON, 14 January 2009 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: 
HIK) is a fast growing multinational pharmaceutical group focused on developing, 
manufacturing and marketing a broad range of generic and in-licensed patented 
pharmaceutical products. 
 
 
The Board expects operating performance for 2008 to have been in line with our 
expectations as described in our last communication with the market in 
November.  For the year ending 31 December 2008 revenue growth is expected to be 
approximately 30%.  Since Hikma was listed on the London Stock Exchange in 
2005, revenues have grown at a compound annual rate of more than 29%. 
 
 
We reported last year that difficult trading conditions in the US for our 
Generics business led to an operating loss in that segment for the first half of 
the year.  We took a number of management initiatives to improve performance 
and, as expected, will report a loss for the year as a whole for Generics but 
have returned that business segment to profitability for the last quarter of 
2008.  With the benefits of these initiatives and some recent improvement in 
trading conditions, we expect the Generics business to remain in profit in 2009. 
 
 
Our operating cash flow performance has improved during the second half of the 
year and as a result our net debt levels have decreased since June. 
 
 
Hikma will enter its close period on Friday 16 January ahead of the announcement 
of its results for the twelve months ending 31 December 2008, to be made on 17 
March 2009. 
 
 
- ENDS - 
Enquiries: 
 
 
+--------------------------------+------------------------------------+ 
| Hikma Pharmaceuticals PLC      |                                    | 
+--------------------------------+------------------------------------+ 
| Peter Laing                    | +44 207 399 2767                   | 
| Investor Relations             |                                    | 
+--------------------------------+------------------------------------+ 
 
 
+--------------------------------+------------------------------------+ 
| Brunswick Group                |                                    | 
+--------------------------------+------------------------------------+ 
| Jon Coles / Justine McIlroy    | +44 207 404 5959                   | 
+--------------------------------+------------------------------------+ 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed products. Hikma operates through three 
businesses: "Branded", "Injectables" and "Generics", based principally in the 
Middle East and North Africa ("MENA"), where it is a market leader and sells 
across 17 countries, the United States and Europe. In 2007, Hikma achieved 
revenues of $449 million and profit attributable to shareholders of $63 million. 
At 31 December 2007, the Group had over 3,000 employees. For news and other 
information, please visit www.hikma.com. 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 TSTKGGMMVFLGLZM 
 

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024